Form 4: Halozyme Therapeutics Executive Reports Stock Transactions

Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, reports the vesting and settlement of restricted stock units and associated tax withholding.

Summary

• On February 23, 2025, Michael J. LaBarre, SVP and Chief Technical Officer of Halozyme Therapeutics, engaged in transactions involving the company's stock.
• Specifically, 4,747 restricted stock units vested and were settled for common stock.
• Additionally, 2,410 shares were disposed of to cover tax withholding obligations at a price of $57.75 per share.
• Following these transactions, LaBarre directly owns 195,453 shares of Halozyme Therapeutics common stock and 14,238 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing reflecting standard executive compensation practices. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may be interested in insider transactions as an indicator of management's confidence in the company.
• The transactions have a minor impact on the total number of shares outstanding.

Key Dates

Keywords

Form 4, Halozyme Therapeutics, Stock Transaction, Restricted Stock Units, Beneficial Ownership, Insider Trading